Cargando…

Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker

Oral dryness as a side effect of certain drugs is increasing. The aim of this study was to examine the change of the protein ingredient in saliva of oral dryness patients caused by calcium blocker. Six patients taking calcium blocker and six healthy elderly were enrolled. Unstimulated salivary flow...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuhashi, Fumi, Morita, Takao, Toya, Shuji, Sato, Ritsuko, Watarai, Yuko, Koide, Kaoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709676/
https://www.ncbi.nlm.nih.gov/pubmed/33036340
http://dx.doi.org/10.3390/geriatrics5040070
_version_ 1783617801955573760
author Mizuhashi, Fumi
Morita, Takao
Toya, Shuji
Sato, Ritsuko
Watarai, Yuko
Koide, Kaoru
author_facet Mizuhashi, Fumi
Morita, Takao
Toya, Shuji
Sato, Ritsuko
Watarai, Yuko
Koide, Kaoru
author_sort Mizuhashi, Fumi
collection PubMed
description Oral dryness as a side effect of certain drugs is increasing. The aim of this study was to examine the change of the protein ingredient in saliva of oral dryness patients caused by calcium blocker. Six patients taking calcium blocker and six healthy elderly were enrolled. Unstimulated salivary flow rate, protein concentration, and flow rate of protein were measured and compared between the patients taking calcium blocker and healthy elderly. iTRAQ (Isobaric Tag for Relative and Absolute Quantitation) proteomic analysis was performed to extract the salivary protein changed in patient taking calcium blocker, and the intensities of Western blotting products were quantified (unpaired t-test). Unstimulated salivary flow rate was significantly lower on patients taking calcium blocker (p < 0.01). Protein concentration tended to be higher and the flow rate of protein tended to be lower on patients. As the result of iTRAQ proteomic analysis, calmodulin-like protein 3, glutathione S-transferase P, and keratin type I cytoskeletal 13 increased characteristically in patient taking calcium blocker, and the expression in calmodulin-like protein 3 was significantly larger (p < 0.01). The results of this study indicated that calmodulin-like protein 3 increased in patients taking calcium blocker and could be a salivary biomarker for oral dryness caused by calcium blocker.
format Online
Article
Text
id pubmed-7709676
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77096762020-12-03 Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker Mizuhashi, Fumi Morita, Takao Toya, Shuji Sato, Ritsuko Watarai, Yuko Koide, Kaoru Geriatrics (Basel) Article Oral dryness as a side effect of certain drugs is increasing. The aim of this study was to examine the change of the protein ingredient in saliva of oral dryness patients caused by calcium blocker. Six patients taking calcium blocker and six healthy elderly were enrolled. Unstimulated salivary flow rate, protein concentration, and flow rate of protein were measured and compared between the patients taking calcium blocker and healthy elderly. iTRAQ (Isobaric Tag for Relative and Absolute Quantitation) proteomic analysis was performed to extract the salivary protein changed in patient taking calcium blocker, and the intensities of Western blotting products were quantified (unpaired t-test). Unstimulated salivary flow rate was significantly lower on patients taking calcium blocker (p < 0.01). Protein concentration tended to be higher and the flow rate of protein tended to be lower on patients. As the result of iTRAQ proteomic analysis, calmodulin-like protein 3, glutathione S-transferase P, and keratin type I cytoskeletal 13 increased characteristically in patient taking calcium blocker, and the expression in calmodulin-like protein 3 was significantly larger (p < 0.01). The results of this study indicated that calmodulin-like protein 3 increased in patients taking calcium blocker and could be a salivary biomarker for oral dryness caused by calcium blocker. MDPI 2020-10-07 /pmc/articles/PMC7709676/ /pubmed/33036340 http://dx.doi.org/10.3390/geriatrics5040070 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mizuhashi, Fumi
Morita, Takao
Toya, Shuji
Sato, Ritsuko
Watarai, Yuko
Koide, Kaoru
Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title_full Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title_fullStr Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title_full_unstemmed Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title_short Protein Ingredient in Saliva on Oral Dryness Patients Caused by Calcium Blocker
title_sort protein ingredient in saliva on oral dryness patients caused by calcium blocker
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709676/
https://www.ncbi.nlm.nih.gov/pubmed/33036340
http://dx.doi.org/10.3390/geriatrics5040070
work_keys_str_mv AT mizuhashifumi proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker
AT moritatakao proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker
AT toyashuji proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker
AT satoritsuko proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker
AT wataraiyuko proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker
AT koidekaoru proteiningredientinsalivaonoraldrynesspatientscausedbycalciumblocker